Last month, Samyang Holdings, which merged with Samyang Biopharm, a subsidiary specializing in pharmaceutical bio, is expanding generics for anticancer drug business.

In January, following generic for Votrient (Pazopanib HCl), a kidney cancer treatment, it is also developing generic for Sutene (Sunitinib Malate). Votrient and Sutene currently do not have generics in Korea.

The MFDS approved the protocol of bioequivalence study for SYO-1767 applied by Samyang Holdings on the 30th of last month. SYO-1767 is presumed to be generic for Sutene in that the target disease name of this drug is the same as Pfizer's Sutene. Sutene, which was approved in Korea in 2006, is used for various carcinomas